- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Samsung to Launch AI-Powered OB-GYN Ultrasound at Society for Maternal-Fetal Medicine Conference
Designed for advanced OB-GYN applications, the Samsung Z20 ultrasound platform reportedly provides a combination of artificial intelligence (AI) tools and enhanced ergonomics.
Offering a variety of artificial intelligence (AI) features to bolster workflow efficiency, Samsung plans to launch the Z20 ultrasound system at the Society for Maternal-Fetal Medicine conference (continuing today through February 1) in Denver.
Samsung noted the Z20 ultrasound’s deep learning feature Live ViewAssist™ provides automated labeling of up to 47 anatomic structures, performs 46 key measurements and facilitates up to a 94 reduction in keystrokes.
The Z20 ultrasound system, which will be launched at he upcoming Maternal-Fetal Medicine conference in Denver, reportedly performs 46 key measurements and provides automatic labeling of 47 anatomic structures for OB-GYN exams, according to Samsung, the developer of the Z20 ultrasound system. (Photo courtesy of Samsung.)
Employing advanced software beamforming, the Z20 ultrasound system offers enhanced diagnostic accuracy, even in cases involving patients with a high body mass index (BMI), according to Samsung. The company added that recent independent testing of the Z20 device found that it met or exceeded all standard ergonomic measurements.
“The Z20 represents a significant technology milestone for both Samsung and the broader ultrasound industry. … (It) also reflects our commitment to breaking the iron triangle of healthcare cost, access, and quality by integrating the Z20 with a digital ecosystem for telesonography, reporting, and fleet management,” noted Tracy Bury, the vice president and head of ultrasound USA and global growth initiatives at Samsung Medison.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
